E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Researchers suggest that microbiome-based therapies should be tailored to regional populations rather than adopting approaches developed solely from Western populations.
imphoenix82
Amygdala Neurosciences is initially developing ANS-858 as a potential treatment for alcohol use disorder and other substance use disorders.
imphoenix82
The ANVISA GMP certification will help Innogen accelerate the registration and commercial launch of Efsubaglutide alfa across all PIC/S-aligned emerging markets, including Hong Kong, Southeast Asia and Latin America.
imphoenix82
Novo Nordisk alleges Lilly’s advertisements for Zepbound and Mounjaro mislead consumers by comparing the drugs with lower-dose versions of Wegovy and Ozempic.
imphoenix82
The future of obesity care will involve multidisciplinary collaboration between physicians, dieticians, fitness professionals and patient support teams, says Ajanta Pharma.
imphoenix82
Eligible Medicare beneficiaries can now access Wegovy in both injection and oral forms for a monthly copayment of $50 through the programme, which will remain in place until the end of 2027.
imphoenix82
Lilly sees retatrutide as part of a broader portfolio approach to obesity care alongside its existing therapies Zepbound (tirzepatide) and Foundayo (orforglipron).
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
